Evidence map›Paper›PMID 39208026›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2024

Prostate Cancer Disparities in Clinical Characteristics and Survival among Black and Latino Patients Considering Nativity: Findings from the California Cancer Registry.

Alexis R Freedland, Joel Sanchez Mendez, Lihua Liu, Ann S Hamilton, Juanjuan Zhang, Amie E Hwang, Leslie Ballas, Andre Luis Abreu, Dennis Deapen, Mariana C Stern

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alexis R Freedland *Department of Epidemiology and Biostatistics, Program in Public Health, University of California, Irvine, Irvine, California.ORCID 0000-0001-5277-5113
Joel Sanchez Mendez *Department of Population and Public Health Sciences, Keck School of Medicine of USC, University of Southern California, Los Angeles, California.ORCID 0000-0001-5552-1020
Lihua LiuDepartment of Population and Public Health Sciences, Keck School of Medicine of USC, University of Southern California, Los Angeles, California.ORCID 0000-0003-2252-8407
Ann S HamiltonDepartment of Population and Public Health Sciences, Keck School of Medicine of USC, University of Southern California, Los Angeles, California.ORCID 0000-0001-5898-2308
Juanjuan ZhangDepartment of Population and Public Health Sciences, Keck School of Medicine of USC, University of Southern California, Los Angeles, California.ORCID 0009-0007-6900-8659
Amie E HwangDepartment of Population and Public Health Sciences, Keck School of Medicine of USC, University of Southern California, Los Angeles, California.ORCID 0000-0002-5538-131X
Leslie BallasDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0009-0008-9222-6782
Andre Luis AbreuDepartment of Urology, Keck School of Medicine, Los Angeles, California.ORCID 0000-0002-9167-2587
Dennis DeapenDepartment of Population and Public Health Sciences, Keck School of Medicine of USC, University of Southern California, Los Angeles, California.ORCID 0000-0002-0037-0277
Mariana C SternDepartment of Population and Public Health Sciences, Keck School of Medicine of USC, University of Southern California, Los Angeles, California.ORCID 0000-0001-9777-4683

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Tissue Modeling & Drug Development Shared Resources CoreU54CA233444 · NCI · UNIVERSITY OF FLORIDA · PI Naziheh Assarzadegan, Chanita A. Hughes-Halbert · 2018 to 2026
$12.1M
Tissue Modeling CoreU54CA233465 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JOYCE M RICHEY · 2018 to 2026
$11.9M
Diagnosing clinically-significant prostate cancer in African American men: Systematic random versus MR-image-fusion guided biopsyR01CA205058 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GILL, INDERBIR, STERN, MARIANA C · 2016 to 2019
$2.1M
National Cancer Institute (NCI) P30CA014089National Cancer Institute (NCI) U54CA233465NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INCI NIH HHS P30 CA014089NCI NIH HHS R01 CA205058NCI NIH HHS U54 CA233444NCI NIH HHS U54 CA233465
6 · The paper itself

Abstract

backgroundWe investigated clinical characteristics and prostate cancer survival patterns among Latino patients considering nativity compared with non-Latino Black (NLB) and non-Latino White (NLW) patients.

methodsWe used data from the California Cancer Registry (1995-2021), which included 347,540 NLW, 50,032 NLB, and 75,238 Latino patients with prostate cancer. Frequencies of sociodemographic and clinical variables were assessed using χ2 tests. Multivariable regression models were fitted to evaluate determinants of treatment reception, Gleason upgrade, and survival differences. Exploratory analyses were conducted grouping Latino cases into US born and non-US born by country of origin.

resultsCompared with NLW, NLB cases had the greatest proportion of younger patients, whereas non-US-born Latino patients had the greatest proportion of low socioeconomic status and uninsured patients. Non-US-born Latinos showed a greater proportion of diagnoses completed with <6 core biopsies, Gleason >8, stage IV tumors, and metastasis. Multivariable analyses showed that compared with NLW, Latino patients were as likely to receive treatment, whereas NLB cases were less likely (OR = 0.81; 95% confidence interval, 0.67-0.98; P = 0.029). Compared with NLW, non-US-born Latino cases were less likely to die of prostate cancer (HR = 0.78; 95% confidence interval, 0.64-0.94; P = 0.011), with no difference reported for NLB cases.

conclusionsConsidering sociodemographic and clinical characteristics, non-US-born Latino patients with prostate cancer had better survival than NLW. This highlights the need to identify key determinants of these survival differences and the importance of sociodemographic and clinical determinants in survival disparities. IMPACT: Our study emphasizes the importance of considering nativity among Latino patients to understand prostate cancer disparities and outcomes in this population.

Indexed as

Black or African AmericanHispanic or LatinoProstatic NeoplasmsAgedCaliforniaHealthcare DisparitiesHumansMaleMiddle AgedRegistries

Identifiers

PMID39208026
PMCPMC12468573

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.